CIK 0000730272
- Large accelerated filer
REPLIGEN CORP
Sign in to watch- Ticker
- RGEN
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 042729386
- Phone
- +1 781-449-9560
- Business address
- 41 SEYON STREET, BUILDING 1, SUITE 100, WALTHAM, MA, 02453
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $4,976,580
- in 4 filings, $5.0M under 10b5-1 plans
Net −$4,976,580. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2020-09-10 | Hunt Anthony Chief Executive Officer | Exercise or conversion · Stock Option (Right to Buy) | −45,351 | 20,000 | ||
| 2020-08-06 | KURIYEL RALF Senior VP, R&D | Exercise or conversion | +5,000 | $33.87 | $169K | 31,089 |
| 2020-08-06 | KURIYEL RALF Senior VP, R&D | Sale | −5,000 | $153.79 | $769K | 26,089 |
| 2020-08-06 | KURIYEL RALF Senior VP, R&D | Exercise or conversion · Stock Option (Right to Buy) | −5,000 | 5,850 | ||
| 2020-07-31 | RYAN THOMAS F JR Director | Exercise or conversion | +2,109 | $67.71 | $143K | 4,559 |
| 2020-07-31 | RYAN THOMAS F JR Director | Sale | −2,109 | $151.96 | $320K | 2,450 |
| 2020-07-31 | RYAN THOMAS F JR Director | Sale | −986 | $151.77 | $150K | 1,464 |
| 2020-07-31 | RYAN THOMAS F JR Director | Grant or award · Stock Option (Right to Buy) | +2,109 | 0 | ||
| 2020-06-18 | DAWES KAREN A Director | Sale | −2,677 | $113.58 | $304K | 116,762 |
| 2020-06-18 | DAWES KAREN A Director | Sale | −5,243 | $114.49 | $600K | 111,519 |
| 2020-06-18 | DAWES KAREN A Director | Sale | −8,217 | $115.76 | $951K | 103,302 |
| 2020-06-18 | DAWES KAREN A Director | Sale | −2,568 | $116.56 | $299K | 100,734 |
| 2020-06-11 | EGLINTON MANNER CARRIE Director | Grant or award · Stock Option (Right to Buy) | +2,794 | 2,794 | ||
| 2020-05-21 | Hunt Anthony Chief Executive Officer | Exercise or conversion | +7,916 | $16.55 | $131K | 238,157 |
| 2020-05-21 | Hunt Anthony Chief Executive Officer | Exercise or conversion | +39,037 | $24.98 | $975K | 277,194 |
| 2020-05-21 | Hunt Anthony Chief Executive Officer | Sale | −16,496 | $139.17 | $2.3M | 260,698 |
| 2020-05-21 | Hunt Anthony Chief Executive Officer | Sale | −28,980 | $140.04 | $4.1M | 231,718 |
| 2020-05-21 | Hunt Anthony Chief Executive Officer | Sale | −1,377 | $140.99 | $194K | 230,341 |
| 2020-05-21 | Hunt Anthony Chief Executive Officer | Sale | −100 | $141.58 | $14K | 230,241 |
| 2020-05-21 | Hunt Anthony Chief Executive Officer | Exercise or conversion | +3,086 | $32.40 | $100K | 233,327 |
Page 33 of 42 · 832 trades